Feature

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.

July 16, 2024

Feature

Perimeter aims to transform cancer surgery with ultra-high-res imaging tools

Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) is developing breakthrough ultra-high-resolution, real-time, advanced imaging tools to assist cancer surgeons in achieving clean margins during initial surgery.

July 2, 2024

Feature

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat cancer, improving...

June 25, 2024

Feature

OneMedNet transforming real-world data to advance the future of medicine and redefine standards in patient care

OneMedNet (NASDAQ:ONMD) is delivering seamless access to regulatory-grade imaging real-world data (RWD) by employing its proprietary iRWD network and platform to de-identify, search, and curate data revealing an...

June 4, 2024

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

Perimeter aims to transform cancer surgery with ultra-high-res imaging tools

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

OneMedNet transforming real-world data to advance the future of medicine and redefine standards in patient care

NEWS

ZyVersa highlights published data supporting potential of IC 100 for obesity care

Transgene and ProBioGen partner to advance cancer vaccine development

Essa terminates Phase 2 study of Masofaniten combined with Enzalutamide in mCRPC

FDA grants Type C meeting with Kazia on next steps for Paxalisib in GBM

OSE announces positive Phase 2 results of Lusvertikimab for UC

Lifecore appoints Thomas Guldager as VP operations, names Jackie Klecker as EVP quality

Profound’s 2025 TULSA CMS reimbursement level leapfrogs all other prostate disease modalities

FDA approves launch of clinical study for Envoy’s breakthrough implanted hearing device

USPTO issues NOA for Starton’s STAR-LLD continuous delivery system

Just a few of the companies we’ve highlighted along the way

General

More